Skip to main content

Table 1 Baseline characteristics for patients with metastatic breast cancer receiving everolimus exemestane in first-, second-, and/or third-line of treatment in the Flatiron Health database, 2012–2018

From: Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy

  1. *Numbers are obscured to protect patient privacy
  2. *Not mutually exclusive; sum > n for each group